Article
XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53- mediated caspase-dependent apoptosis
Registro en:
BOONS, Eline et al. XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53- mediated caspase-dependent apoptosis. Blood Cancer Journal, v. 11, p. 1-5, 2021.
2044-5385
10.1038/s41408-021-00409-3
10.1038/s41408-021-00409-3
Autor
Boons, Eline
Nogueira, Tatiane C.
Dierckx, Tim
Menezes, Soraya Maria
Jacquemyn, Maarten
Tamir, Sharon
Landesman, Yosef
Vallve, Maria Lourdes Farré
Bittencourt, Achiléa Lisboa Candido
Kataoka, Keisuke
Ogawa, Seishi
Snoeck, Robert
Andrei, Graciela
Van Weyenbergh, Johan
Daelemans, Dirk
Resumen
Vallve, Maria Lourdes Farré. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. 1KU Leuven Department of Microbiology, Immunology and Transplantation,
Laboratory of Virology and Chemotherapy, Rega Institute, B-3000 Leuven,
Belgium. 2KU Leuven Department of Microbiology, Immunology and
Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega
Institute, B-3000 Leuven, Belgium. 3Karyopharm Therapeutics, Newton, MA,
USA. 4Instituto de Pesquisa Goncalo Moniz, Oswaldo Cruz Foundation
(FIOCRUZ), Salvador, Bahia, Brazil. 5HUPES, Federal University of Bahia (UFBA),
Salvador-Bahia, Brazil. 6Department of Pathology and Tumor Biology, Kyoto
University, Kyoto, Japan FWO (grant G0D6817N) and KU Leuven (“Vaast Leysen Leerstoel
voor Infectieziekten in Ontwikkelingslanden”). S.O. is supported by Grant-in-Aid
from the Japan Agency for Medical Research and Development
[JP119cm0106501h0004, JP119cm0106501h0004], Grant-in-Aid for Scientific
Research (KAKENHI 15H05909).